Core A measures serum, serum ultrafiltrate (UF), plasma and urine stone risk chemistries and calculates urine supersaturations (SS) for patients studied in Projects 1 and 2. These measurements are used for fulfillment of aims within all three projects and six program aims carried out within the overall program project. Plasma GLP-1, renin, and plasma and urine cAMP will also be measured by Core A for Project 1. Blood and urine samples are processed and shipped for assay of lithium done in Core B and for measurement of plasma glucagon, parathyroid hormone (PTH) and 1,25 vitamin D (performed by LabCorp). Sample aliquots are stored at -80?C for future use. All laboratory data from Core A for all projects are consolidated into a single database with daily backup for security and ease of analysis. Ultimately, data from the other projects and cores (e.g. histology, biopsy, stone analysis etc.) will be consolidated into our database so that it can be analyzed along with serum and urine data.

Public Health Relevance

Core A performs blood and urine assays to characterize the metabolic abnormalities in all patients biopsied in Project 2. Core A also performs assays for studies of renal handling of minerals in stone formers and controls in Project 1, especially changes associated with eating, in order to uncover the abnormalities of renal calcium reabsorption that promote both calcium stone formation and renal papillary calcifications.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Program Projects (P01)
Project #
5P01DK056788-12
Application #
8382166
Study Section
Special Emphasis Panel (ZDK1-GRB-R)
Project Start
Project End
Budget Start
2012-08-01
Budget End
2013-07-31
Support Year
12
Fiscal Year
2012
Total Cost
$231,190
Indirect Cost
$82,941
Name
University of Chicago
Department
Type
DUNS #
005421136
City
Chicago
State
IL
Country
United States
Zip Code
60637
Borofsky, Michael S; Paonessa, Jessica E; Evan, Andrew P et al. (2016) A Proposed Grading System to Standardize the Description of Renal Papillary Appearance at the Time of Endoscopy in Patients with Nephrolithiasis. J Endourol 30:122-7
Witzmann, Frank A; Evan, Andrew P; Coe, Fredric L et al. (2016) Label-free proteomic methodology for the analysis of human kidney stone matrix composition. Proteome Sci 14:4
Handa, Rajash K; Lingeman, James E; Bledsoe, Sharon B et al. (2016) Intraluminal measurement of papillary duct urine pH, in vivo: a pilot study in the swine kidney. Urolithiasis 44:211-7
Borofsky, Michael S; Wollin, Daniel A; Reddy, Thanmaya et al. (2016) Salvage Percutaneous Nephrolithotomy: Analysis of Outcomes following Initial Treatment Failure. J Urol 195:977-81
Hoover, Robert S; Tomilin, Viktor; Hanson, Lauren et al. (2016) PTH modulation of NCC activity regulates TRPV5 Ca2+ reabsorption. Am J Physiol Renal Physiol 310:F144-51
Williams Jr, James C; Worcester, Elaine; Lingeman, James E (2016) What can the microstructure of stones tell us? Urolithiasis :
Zisman, Anna L; Evan, Andrew P; Coe, Fredric L et al. (2015) Do kidney stone formers have a kidney disease? Kidney Int 88:1240-1249
Evan, Andrew P; Worcester, Elaine M; Coe, Fredric L et al. (2015) Mechanisms of human kidney stone formation. Urolithiasis 43 Suppl 1:19-32
Bhojani, Naeem; Paonessa, Jessica E; Hameed, Tariq A et al. (2015) Nephrocalcinosis in Calcium Stone Formers Who Do Not have Systemic Disease. J Urol 194:1308-12
Evan, Andrew P; Worcester, Elaine M; Williams Jr, James C et al. (2015) Biopsy proven medullary sponge kidney: clinical findings, histopathology, and role of osteogenesis in stone and plaque formation. Anat Rec (Hoboken) 298:865-77

Showing the most recent 10 out of 128 publications